$4 Million and Years of Hype | GenomeWeb

According to SEC filings, 23andMe gave $4 million to one executive officer, blogs BNET's Rachel Lehmann-Haupt. That money was payment to a company officer for a loan, but Lehmann-Haupt notes that "given the fact that it’s a rocky time financially for 23andMe, it also seems like a bad time to lay out so much cash to one person." Indeed, in the past year, Linda Avey left, the company had a round of layoffs, and increased the price of their products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.